Abstract
Executive Summary
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer
treatment but Camptosar and Eloxatin quickly established themselves as
components of gold-standard therapy. The advent of Avastin and Erbitux
heralded a new era in the disease management, and the emergence of other
molecular targeted agents should further push survival to an unprecedented
level in the coming years.
There are today more than 250 therapeutics targeting colorectal cancer, from
early preclinical to marketed drugs. Colorectal Drug Pipeline Update lists all
drugs and gives you a progress analysis on each one of them. Identified drugs
are linked to 134 different targets. These targets are further categorized on
the CD-ROM by 47 classifications of molecular function and with pathway
referals to BioCarta, KEGG and NetPath. Read more below on how the Colorectal
Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
View Cart
